Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines
复制标题
DOI：
10.1002/humu.20730
复制
发表时间：
2008-05-01
期刊：
影响因子：
3.9
通讯作者：
Sanchez-Cespedes, Montse
中科院分区：
文献类型：
--
作者：
Medina, Pedro P.;Romero, Octavio A.;Sanchez-Cespedes, Montse
SWI/SNF染色质重塑复合物的组分，如INI1，在人类癌症中失活，因此作为肿瘤抑制因子发挥作用。在此，我们对59种最常见组织病理学类型的肺癌细胞系中编码该复合物ATP酶的BRG1（SMARCA4）的整个编码序列进行了突变筛选。在24%的癌细胞系中检测到突变，其中许多是在常用于肺癌研究的细胞中。所有突变均为纯合突变，且大多数预测会产生截短的蛋白质。与小细胞肺癌（SCLC）类型（1/19，5%）相比，非小细胞肺癌（NSCLC）类型（13/37，35%）中的这种改变明显更频繁（P
Components of the SWI/SNF chromatin,remodeling complex, such as INI1, are inactivated in human cancer and, thus, act as tumor suppressors. Here we screened for mutations the entire coding sequence of BRG1 (SMARCA4), which encodes the ATPase of the complex, in 59 lung cancer cell lines of the most common histopathological types. Mutations were detected in 24% of the cancer cell lines, many of them in cells commonly used for lung cancer research. All mutations were homozygous and most predicted truncated proteins. The alterations were significantly more frequent in the non-small-cell lung cancer (NSCLC) type (13/37, 35%) as compared to the small,cell lung cancer (SCLC) type (1/19, 5%) (P